Efficacy and Tolerability of Travoprost 0.004/Timolol 0.5 Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

Table 2

Treatment-emergent AEs with incidence ≥2% during the study (safety population).

MedDRA preferred term	TTFC; ()	Beta-blocker; ()
Total AEs, (%)	18 (22.2)	9 (12.0)
Ocular hyperemia	5 (6.2)	0
Dry eye	2 (2.5)	2 (2.7)
Eye pruritus	4 (4.9)	0 (0.0)
Nasopharyngitis	2 (2.5)	2 (2.7)
Influenza	0	2 (2.7)

A subject with more than one event in a specific category was only counted once. Number of events based on MedDRA coding; due to splitting of terms, number of MedDRA terms can be different from number of reported events. MedDRA version 18.0.
AEs, adverse events; MedDRA, Medical Dictionary for Regulatory Activities; TTFC, travoprost 0.004%/timolol 0.5% fixed-dose combination.